• About
    • Viatris in Europe
      • Unlocking European patients access to medicines
    • Viatris' Manufacturing Footprint
    • Memberships and Partnerships
    • Building Sustainable Access At Scale
  • Policy
    • Policy for Access
      • Preserving Patients Access to Off-Patent Medicines
      • Protecting Access to Essential Antibiotics
      • VAM: Improving Patient Outcomes with Existing Medicines
      • Securing Access to Critical Medicines
      • Scalable European Model Tackling Antimicrobial Resistance
    • Green Deal
      • Environmental Stewardship
    • Strategic Autonomy & Industrial Strategy
      • Investing in Supply Resilience to Secure Access
      • Best Procurement Practices
    • Digital Strategy
      • European Health Data Space
  • Public Health
    • AMR
    • NCD Academy
    • Tackling Noncommunicable Diseases
    • Advancing Access to Anaphylaxis Treatment
    • Influenza
    • Infectious Diseases
    • COVID-19
  • Conversation
Show Menu

Transatlantic partnership is key for improved patient access to medicines

By Victor Mendonça

Boosting competitiveness for American companies in Europe and tapping into the Transatlantic partnership for collaborative solutions to pressing challenges —these are key takeaways from a recent dynamic week of meetings in Brussels organized by the United States Chamber of Commerce.

Viatris joined 16 other companies in meetings including with the Ambassador Gitenstein, European Commission Executive Vice President Šefčovič and senior Commission and Council officials, reinforcing our commitment to enable access to medicines for patients in Europe.

The current Pharmaceutical Legislation review is the centerpiece of the European health space, and during the meetings we took the opportunity to share our views around how the review presents a unique opportunity to advance equitable access to medicines, while creating the conditions for a predictable, resilient, and future-proof pharmaceutical market.

Take Sustainability and the Green Transition as an example. According to the World Health Organization, climate change threatens to undo the last 50 years of progress in development and global health. With many Sustainability files still open in the EU, we shared our commitment to doing our part to advance sustainable practices and minimize our environmental footprint, while at the same time further building collaboration on the importance of safeguarding the reliable supply of medicines and more resilient healthcare systems. In relation to the Pharmaceutical Legislation, we encourage a pragmatic approach to environmental risk assessments, focusing on efficient use of limited resources and prioritizing patient access to medicines.

Securing access to medicines for European patients hits close to home for me as a proud European. For a global pharmaceutical company like Viatris, with a portfolio comprising more than 1,400 approved molecules across all major therapeutic areas and supplying over 35 billion doses of medicine in Europe each year, simplifying the regulatory burden is a critical step to enable patient access. This could also help improve European competitiveness as an important pharmaceutical research, development, and manufacturing location. Viatris supports the simplification of the European regulatory environment, including recognizing the significant potential for digitalization in improving coordination among Member States and European Institutions.

I am energized by the collaborative spirit in these recent meetings with EU policy makers. At Viatris we welcome such opportunities to engage in constructive discussions and foster partnership in advancing our mission to improve access to medicines. We recognize there's more to accomplish, and we're genuinely committed to doing our part, for the benefit of patients in Europe and around the world.

Leaving the Viatris site

You are now leaving the Viatris page for a Viatris affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Viatris affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Continue
Cancel

Viatris Policy and Government Affairs

  • Privacy Notice
  • Cookie Notice
  • Terms of Use
  • Contact Us
  • Privacy Notice
    • Dutch
    • French
  • Cookie Notice
    • Dutch
    • French
  • Terms of Use
  • Contact Us
© 2025 Viatris
Created on: 6/25/2021
Updated on: 2/7/2024